{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1+Clinical+Trial&page=3",
    "query": {
      "condition": "Phase 1 Clinical Trial",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 9283,
    "total_pages": 929,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1+Clinical+Trial&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1+Clinical+Trial&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T23:48:56.187Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05590377",
      "title": "A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Modakafusp Alfa",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2023-01-23",
      "completion_date": "2024-05-22",
      "has_results": true,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 13,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Fort Wayne, Indiana + 10 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05590377"
    },
    {
      "nct_id": "NCT07156227",
      "title": "Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Recurrent Hypopharyngeal Squamous Cell Carcinoma",
        "Recurrent Laryngeal Squamous Cell Carcinoma",
        "Recurrent Oral Cavity Squamous Cell Carcinoma",
        "Recurrent Oropharyngeal Squamous Cell Carcinoma",
        "Recurrent Paranasal Sinus Squamous Cell Carcinoma",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage III Hypopharyngeal Carcinoma AJCC v8",
        "Stage III Laryngeal Cancer AJCC v8",
        "Stage III Lip and Oral Cavity Cancer AJCC v8",
        "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage III Sinonasal Cancer AJCC v8",
        "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage IVA Hypopharyngeal Carcinoma AJCC v8",
        "Stage IVA Laryngeal Cancer AJCC v8",
        "Stage IVA Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVA Sinonasal Cancer AJCC v8",
        "Stage IVB Hypopharyngeal Carcinoma AJCC v8",
        "Stage IVB Laryngeal Cancer AJCC v8",
        "Stage IVB Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVB Sinonasal Cancer AJCC v8",
        "Unresectable Head and Neck Squamous Cell Carcinoma",
        "Unresectable Hypopharyngeal Squamous Cell Carcinoma",
        "Unresectable Laryngeal Squamous Cell Carcinoma",
        "Unresectable Oral Cavity Squamous Cell Carcinoma",
        "Unresectable Oropharyngeal Squamous Cell Carcinoma",
        "Unresectable Paranasal Sinus Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Camonsertib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2027-02-13",
      "completion_date": "2029-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Irvine, California • Lexington, Kentucky + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07156227"
    },
    {
      "nct_id": "NCT00344786",
      "title": "Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CNF2024 (BIIB021)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2006-02",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2009-06-05",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 3,
      "location_summary": "San Diego, California • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00344786"
    },
    {
      "nct_id": "NCT02035605",
      "title": "A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "ALN-AT3SC",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 51,
      "start_date": "2014-01-20",
      "completion_date": "2017-07-20",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02035605"
    },
    {
      "nct_id": "NCT05797805",
      "title": "A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tegavivint",
          "type": "DRUG"
        },
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Iterion Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2023-09-13",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Miami, Florida • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05797805"
    },
    {
      "nct_id": "NCT04396873",
      "title": "PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Dementia",
        "Alzheimer's Disease",
        "ALS",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "11C-MC1",
          "type": "DRUG"
        },
        {
          "name": "11C-PS13",
          "type": "DRUG"
        },
        {
          "name": "18f-florbetaben",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 184,
      "start_date": "2021-08-17",
      "completion_date": "2030-10-03",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04396873"
    },
    {
      "nct_id": "NCT03934541",
      "title": "Evaluating the Safety and Immunogenicity of an HIV-1 gp41 MPER-656 Liposome Vaccine in Healthy, HIV-uninfected Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MPER-656 Liposome Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for MPER-656 Liposome Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-08-26",
      "completion_date": "2021-05-26",
      "has_results": true,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • New York, New York + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03934541"
    },
    {
      "nct_id": "NCT07024641",
      "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis B Virus Infection"
      ],
      "interventions": [
        {
          "name": "GIGA-2339",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GigaGen, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2024-11-13",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 12,
      "location_summary": "Chandler, Arizona • Huntington Beach, California • Lake Forest, California + 9 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Lake Forest",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07024641"
    },
    {
      "nct_id": "NCT02391480",
      "title": "A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Breast Cancer",
        "Non-Small Cell Lung Cancer",
        "Acute Myeloid Leukemia (AML)",
        "Multiple Myeloma",
        "Prostate Cancer",
        "Small Cell Lung Cancer",
        "Non-Hodgkins Lymphoma"
      ],
      "interventions": [
        {
          "name": "ABBV-075",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 128,
      "start_date": "2015-04-14",
      "completion_date": "2019-07-05",
      "has_results": false,
      "last_update_posted_date": "2019-11-29",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Duarte, California • Sacramento, California + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02391480"
    },
    {
      "nct_id": "NCT00842088",
      "title": "Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "HQK-1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HemaQuest Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "12 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-08-01",
      "last_synced_at": "2026-11-18T23:48:56.187Z",
      "location_count": 8,
      "location_summary": "Madison, Alabama • Oakland, California • Daytona Beach, Florida + 5 more",
      "locations": [
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00842088"
    }
  ]
}